AEON Biopharma, Inc. (NASDAQ:AEON) Sees Significant Decline in Short Interest

AEON Biopharma, Inc. (NASDAQ:AEON) saw a large decline in short interest in the month of August. As of August 15th, there was short interest totaling 254,000 shares, a decline of 22.6% from the July 31st total of 328,300 shares. Approximately 2.8% of the shares of the company are short sold. Based on an average daily trading volume, of 697,200 shares, the short-interest ratio is currently 0.4 days. Based on an average daily trading volume, of 697,200 shares, the short-interest ratio is currently 0.4 days. Approximately 2.8% of the shares of the company are short sold.

AEON Biopharma Stock Up 3.2%

Shares of NASDAQ AEON opened at $0.75 on Wednesday. The business’s 50 day moving average is $0.77 and its two-hundred day moving average is $0.72. The company has a market cap of $8.72 million, a P/E ratio of 4.16 and a beta of 0.71. AEON Biopharma has a 12 month low of $0.38 and a 12 month high of $115.57.

Institutional Inflows and Outflows

An institutional investor recently raised its position in AEON Biopharma stock. Formidable Asset Management LLC boosted its holdings in AEON Biopharma, Inc. (NASDAQ:AEON) by 76.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 689,182 shares of the company’s stock after buying an additional 299,400 shares during the period. Formidable Asset Management LLC owned approximately 0.86% of AEON Biopharma worth $372,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 22.78% of the company’s stock.

AEON Biopharma Company Profile

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder.